Uncategorized
Ocular Therapeutix™ Presents Data Demonstrating a Clinically-Meaningful Reduction in Intraocular Pressure in Patients with Primary Open Angle Glaucoma or Ocular Hypertension Treated with OTX-TIC at Glaucoma 360 Conference
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, will today present data on OTX-TIC, a long acting travoprost intracameral implant for the treatment of patients with primary open angle glaucoma or ocular hypertension. Data from this Phase 1 clinical trial demonstrated a clinically-meaningful reduction in intraocular